glp 1 agonist microdosing THE GLP-1 PROGRAM Noom expands its GLP-1 range
Description
L., Oriana, H
Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic -cells
Diabetes Care 2015
2022;14:e21536
Authorities are monitoring how these drugs are being used across different care settings, including telehealth platforms and direct-to-consumer models
Patients should continue evidence-based lipid-lowering therapy as recommended by NICE guidelines whilst considering GLP-1 therapy for its licensed indications
